Treace Medical Concepts, Inc. (TMCI)
After hours:
| Previous close | 7.83 |
| Open | 7.95 |
| Bid | 7.69 x 100 |
| Ask | 7.74 x 300 |
| Day's range | 7.55 - 7.96 |
| 52-week range | 3.92 - 23.28 |
| Volume | |
| Avg. volume | 1,473,422 |
| Market cap | 478.703M |
| Beta (5Y monthly) | 0.23 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.88 |
| Earnings date | 06 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.50 |
GlobeNewswireTreace to Report Second Quarter 2024 Financial Results on August 6, 2024
PONTE VEDRA, Fla., July 18, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the second quarter of 2024 after the close of trading on Tuesday, August 6, 2024. Company management will host a conferenc
- GlobeNewswire
Treace to Present at Truist Securities MedTech Conference
Tuesday, June 18, 2024 at 8:00 am Eastern TimePONTE VEDRA, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside
GuruFocus.comDirector Jane Kiernan Acquires 19,356 Shares of Treace Medical Concepts Inc (TMCI)
On May 14, 2024, Director Jane Kiernan purchased 19,356 shares of Treace Medical Concepts Inc (NASDAQ:TMCI), as reported in the SEC Filing.
